Skip to main content
SpringerLink
Log in

Ocular Carteolol

A Review of its Pharmacological Properties, and Therapeutic Use in Glaucoma and Ocular Hypertension

  • Drug Evaluation
  • Published:
Drugs & Aging Aims and scope Submit manuscript

An Erratum to this article was published on 01 January 1994

Summary

Synopsis

Carteolol is a relatively potent nonselective β-adrenoceptor antagonist with partial agonist activity. It is used topically to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Twice-daily ocular administration of carteolol 1 or 2% lowers IOP by approximately 32% on average in patients with these conditions, an efficacy equivalent to that of timolol 0.25 or 0.5%. Carteolol eyedrops lack local anaesthetic activity, appear to cause less local irritation than timolol, and produce less pronounced decreases in heart rate or dyspnoea, possibly due to partial agonist activity. The latter activity may also improve retinal perfusion.

Thus, although additional comparative trials are needed to accurately assess the precise place of carteolol in therapy, this drug offers a useful alternative to timolol in the management of conditions associated with a raised IOP, and may have advantages in older patients with regard to its tolerability profile, although careful monitoring is still wise.

Pharmacodynamic Properties

Carteolol is a nonselective β-adrenoceptor antagonist with partial agonist activity and no local anaesthetic activity.

In healthy volunteers, single ocular administration of carteolol 1 or 2% reduces intraocular pressure (IOP) by a mean of approximately 2 to 5mm Hg (14 to 38% of baseline value). The reduction in IOP lasts for up to 12 hours, with peak effects occurring 4 hours after eyedrop instillation. A crossover effect in the untreated eye is also apparent. Mean IOP decreases by 5 to 10mm Hg (about 20 to 25%) 4 hours after ocular administration of carteolol 1 or 2% in patients with open angle glaucoma or ocular hypertension (IOP > 21mm Hg), and persists for 24 to 48 hours, although IOP over 12 hours appears to be less well controlled than after timolol 0.5%. The mean decrease in IOP is similar following twice-daily ocular administration of carteolol 1 or 2%, or timolol 0.5% after 4 to 10 weeks. 8-Hydroxy-carteolol, the main metabolite of carteolol, appears to be more potent in lowering IOP and possesses greater partial agonist activity.

Studies in volunteers have variously shown that retinal blood perfusion pressure is not significantly decreased, and mean ocular perfusion pressure and retinal blood flow rate may be increased by carteolol. Partial agonist activity and possibly a relaxant effect on endothelial vasculature, as well as the reduced IOP, may contribute to these findings.

In vivo, carteolol elicits fewer pathological changes in the cornea and less readily inhibits epithelial healing than timolol 0.25 and 0.5%, or befunolol 0.5 and 1%. Aqueous humour flow is reduced by carteolol in volunteers, but visual acuity, pupil diameter and anterior chamber volume do not change.

Sufficient carteolol concentrations are achieved systemically following ocular administration to produce systemic β-blockade. Decreases in mean forced expiratory volume in 1 second (FEV1) are less after 1 or 2 carteolol eyedrops (7%) than after timolol (11%) or metipranolol (15%) in patients with asthma. Resting heart rate is unaffected or reduced (mean 16.7%) by single ocular doses of carteolol 1 or 2%, an effect slightly less than that of timolol (mean 18.2%). Systolic blood pressure may be decreased by ocular administration of carteolol (mean 6.5%) while, in common with other β-blocker eyedrops, diastolic pressure is generally unaffected.

Pharmacokinetic Properties

There are very few published data regarding the disposition of carteolol eyedrops in humans, but since most of the ocular dose eventually reaches the systemic circulation, some pharmacokinetic parameters following oral and intravenous delivery are relevant.

First-pass metabolism, about 15% following oral carteolol administration, is bypassed by the ocular route. Total clearance and half-life of carteolol correlate linearly with creatinine clearance. Adjustment of oral dosage is therefore necessary in patients with renal dysfunction, although no data concerning this relevance to the ocular administration of carteolol have been reported.

In humans with normal renal function, 63 to 87% of an oral or intravenous dose of carteolol in total is recovered unchanged in the urine, with the major metabolite, 8-hydroxy-carteolol, comprising 4 to 10%. The volume of distribution of an intravenous dose of carteolol was 4 L/kg in 8 healthy volunteers.

Therapeutic Use

Because of its ability to lower elevated IOP, ocular carteolol has been used clinically to treat patients with ocular hypertension or glaucoma, primarily of the open angle type. Noncomparative trials have shown that carteolol 1 or 2% twice daily reduced mean IOP by a mean of 8.7mm Hg (range 5 to 15mm Hg), a reduction of 32% (19 to 47%) from pretreatment values for up to 14 months in patients with ocular hypertension or glaucoma.

The decrease in IOP during carteolol administration is significantly greater than occurs during placebo use, although open crossover trials have suggested a lesser efficacy of twice-daily carteolol 1% compared with timolol 0.25%, and carteolol 2% compared with timolol 0.5%, this has not been borne out in randomised studies of up to 1 year’s duration. In these trials, carteolol 2% twice daily was equivalent to timolol 0.5%, and carteolol 1% comparable to timolol 0.25%, in that mean IOP was generally reduced by 2 to 4mm Hg (12 to 20%) by both drugs. Greater decreases of between 6 and 10mm Hg (24 to 33%) were also reported. Each drug appears to preserve visual fields to a similar extent. Nevertheless, patients and investigators tended to favour carteolol over timolol based on efficacy and tolerability. IOP was reduced slightly further in previously untreated patients, compared with those changed over from another ocular β-blocker.

Tolerability

Acute eye irritation was reported by 25.8% of 609 patients in a multicentre study before receiving carteolol 1 or 2%, eyelid inflammation by 11.6% of patients and conjunctival oedema by 4.1%; these rates decreased to 1.7, 0.8 and 0.4%, respectively after 2 months’ treatment. Local tolerability of carteolol 2% is better than timolol 0.5%, betaxolol 0.5% and metipranolol 0.6%.

Adverse effects due to systemic absorption of β-blocking concentrations of ocular carteolol are rare in clinical trials, possibly due to selection criteria. Isolated decompensated heart failure, disabling Raynaud’s syndrome, and asthma have been reported during carteolol treatment of glaucoma. Resting heart rates are reduced to a lesser degree than with ocular timolol. Exercise-induced dyspnoea, headache, tiredness and dizziness tended to be less common with ocular carteolol compared with timolol, metipranolol, befunolol or pindolol. Overall incidence of adverse effects was smaller in carteolol (26%) versus timolol recipients (49%) in 1 study.

Dosage and Administration

The manufacturer’s recommended starting dosage of carteolol in the treatment of patients with glaucoma or ocular hypertension is 1 drop of 1% solution into the affected eye(s) twice daily, increasing to the 2% eyedrops twice daily if the initial response is inadequate.

Carteolol eyedrops are contraindicated in patients with cardiac failure or obstructive airways disease, and should be used with caution in those taking systemic β-blocker therapy and those with conditions which may be exacerbated by systemic β-blockade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Araie M, Takase M. Effects of pilocarpine and carteolol, a new beta-adrenergic blocking agent on human aqueous humor dynamics. Nippon Ganka Gakka; Zasshi 84: 2085–2091, 1980

    CAS  Google Scholar 

  • Araie M, Takase M. Effects of S-596 and carteolol, new beta-adrenergic blockers, and flurbiprofen on the human eye: a fluorophotometric study. Graefe’s Archive for Clinical and Experimental Ophthalmology 222: 259–262, 1985

    Article  PubMed  CAS  Google Scholar 

  • Battershill PE, Sorkin EM. Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 36: 601–615, 1988

    Article  PubMed  CAS  Google Scholar 

  • Berlin I, Marcel P, Uzzan B, Millon D, Le Hoang P, et al. A single dose of three different ophthalmic beta-blockers antagonizes the chronotropic effect of isoproterenol in healthy volunteers. Clinical Pharmacology and Therapeutics 41: 622–626, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bienfang DC, Kelly LD, Nicholson DH, Nussenblatt RB. Ophthalmology. New England Journal of Medicine 323: 956–967, 1990

    Article  PubMed  CAS  Google Scholar 

  • Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers. British Journal of Ophthalmology 72: 101–103, 1988

    Article  PubMed  CAS  Google Scholar 

  • Buckley MM-T, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 40: 75–90, 1990

    Article  PubMed  CAS  Google Scholar 

  • Coleman AL, Diehl DLC, Henry MD, Jampel HD, Bachorick PS, et al. Topical timolol decreases plasma high-density lipoprotein cholesterol leve. Archives of Ophthalmology 108: 1260–1263, 1990

    Article  PubMed  CAS  Google Scholar 

  • Collignon-Brach J. Early visual field changes with beta-blocking agents (summary). Survey of Ophthalmology 33 (Suppl.) 429–430, 1989

    Article  PubMed  Google Scholar 

  • Cotton P. Glaucoma: detection before damage, fewer side effects may be possible. Journal of the American Medical Association 264: 1793, 1990

    Article  PubMed  CAS  Google Scholar 

  • Coulangeon LM, Sole M, Menerath JM, Sole P. Debit de l’humeur aqueuse mesure par fluorophotometrie. Etude comparative de l’effet de differents collyres beta-bloquants chez des patients ayant une hypertonie oculaire. Ophtalmologie 4: 156–161, 1990

    PubMed  CAS  Google Scholar 

  • DeSantis L, Polansky JR, Bruce L. Relative differences in beta receptor activity between the cardioselective beta blocker, betaxolol, and nonselective beta blockers. Proceedings of the XXVth International Congress of Ophthalmology, Rome, pp. 1501–1505, May 4–10, 1986, Kugler & Ghedini, Amsterdam, 1987

    Google Scholar 

  • Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmologica 65: 618–621, 1987

    Article  PubMed  CAS  Google Scholar 

  • Duff GR, Graham PA. A double-crossover trial comparing the effects of topical carteolol and placebo on intraocular pressure. British Journal of Ophthalmology 72: 27–28, 1988

    Article  PubMed  CAS  Google Scholar 

  • Duff GR, Newcombe RG. The 12-hour control of intraocular pressure on carteolol 2% twice daily. British Journal of Ophthalmology 72: 890–891, 1988

    Article  PubMed  CAS  Google Scholar 

  • Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 112: 120–125, 1990

    PubMed  CAS  Google Scholar 

  • Flammer J, Etienne R. The effect of β-blockers on differential light sensitivity. Preliminary results. Japanese-French Symposium on Glaucoma, May 29–30, 1985

  • Flammer J, Kitazawa Y, Bonomi L, Mills B, Dorigo M, et al. Carteolol and visual field survival. A randomised multicenter trial. Abstract. 26th International Congresss of Ophthalmology Meeting — Glaucoma Symposium, Singapore, March 16–17, 1990

  • Flury H, Tournoux A, Martenet AC. Verträglichkeit und pharmacokologische Wirksamkeit von antiglaukomatösen augentropfen. Klinische Monatsblätter für Augenheilkunde 188: 573–575, 1986

    Article  PubMed  CAS  Google Scholar 

  • Frishman WH, Covey S. Penbutolol and carteolol: two new beta-adrenergic blockers with partial agonism. Journal of Clinical Pharmacology 30: 412–421, 1990

    PubMed  CAS  Google Scholar 

  • Fujio N, Kitazawa T. Intraocular penetration of l4C-carteolol hydrochloride (β-blocker) in the albino rabbits. Nippon Ganka Gakkai Zasshi 88: 236–241, 1984

    PubMed  CAS  Google Scholar 

  • Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Survey of Ophthalmology 35: 205–218, 1990

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez JP, Clissold SP. Ocular levobunolol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 34: 648–661, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gorgone G, Spina F, Amantia L. Carteolol: preliminary study on ocular pressure-reducing action. Ophthalmologica 187: 171–173, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gregory JEJ, Martin BK. Ocular effects of carteolol and pharmacokinetics in volunteers. Abstract 57. Investigative Ophthalmology and Visual Science 27 (Suppl.): 349, 1986

    Google Scholar 

  • Hasenfuss G, Schäfer-Korting M, Knauf H, Mutschier E, Just H. Pharmacokinetics of carteolol in relation to renal function. European Journal of Pharmacology 29: 461–465, 1985

    Article  CAS  Google Scholar 

  • Hirota A, Mishima H, Kiuchi Y, Nagata A, Kurokawa T, et al. Effect of topical 8-hydroxy carteolol on intraocular pressure and melanin granules. Nippon Ganka Gakkai Zasshi 95: 752–757, 1991

    PubMed  CAS  Google Scholar 

  • Höh H. Lokalanästhetische Wirkung und subjektive Verträglichkeit von Carteolol 2% Metipranolol 0.6% bei Augengesunder. Klinische Monatsblätter für Augenheilkunde 194: 241–248, 1989

    Article  PubMed  Google Scholar 

  • Hommura S, Kono K, Takita K, Kabata T. Influences of topically applied beta-adrenergic blocking agents on tear secretion. In Ferraz de Oliveira LN (Ed.) Ophthalmology Today, pp. 501–502, Elsevier Science Publishers, Amsterdam, 1988

    Google Scholar 

  • Horie T, Takahashi O, Shirato S, Kitazawa Y. Comparison of ocular hypotensive effects of topical timolol and carteolol. Japanese Journal of Clinical Pharmacology 36: 1065–1070, 1982

    Google Scholar 

  • Hugues FC, Le Jeunne C, Munera Y, Dufier JL. Comparison des effets des collyres au carteolol et au metipranolol sur les fonctions ventilatoire et cardiovasculaire de l’asthmatique. Journal Français d’ Ophtalmologie 10: 485–490, 1987

    CAS  Google Scholar 

  • Hurvitz LM, Kaufman PL, Robin AL, Weinreb RN, Crawford K, et al. New developments in the drug treatment of glaucoma. Drugs 41: 514–532, 1991

    Article  PubMed  CAS  Google Scholar 

  • Igarashi H, Katsuta Y, Sawa K, Nakazato Y, Kawasaki T. A comparison of the opacifying effects of carteolol · HCl and 8-hydroxy-carteolol · HCl in the isolated porcine cornea. Fundamental and Applied Toxicology 14: 554–559, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ishizaki T, Ohnishi A, Sasaki T, Chiba K, Suganuma T, et al. Concentration-effect and time-effect relationships of carteolol. European Journal of Clinical Pharmacology 25: 749–757, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ishizaki T, Ohnishi A, Sasaki T, Kushida K, Horai Y, et al. Pharmacokinetics and absolute bioavailability of carteolol, a new β-adrenergic receptor blocking agent. European Journal of Clinical Pharmacology 25: 95–101, 1983b

    Article  PubMed  CAS  Google Scholar 

  • Itoh M, Higashi M, Mizokami K. Cases of discontinuation of β-blocking agents. Ophthalmology 6: 919–923, 1989

    Google Scholar 

  • James IM. Pharmacologic effects of beta-blocking agents used in the management of glaucoma (summary). Survey of Ophthalmology 33 (Suppl.): 453–454, 1989

    Article  PubMed  Google Scholar 

  • Jasper JR, Michel MC, Insel PA. The β-adrenoceptor antagonist carteolol and its metabolite 8-hydroxycarteolol have different intrinsic sympathomimetic activities. British Journal of Clinical Pharmacology 30 (Suppl. 1): 109S–111S, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kitazawa Y, Azuma I, Takase M, Komemushi S. Ocular hypotensive effects of carteolol hydrochloride in primary openangle glaucoma and ocular hypertensive patients; a double-masked cross-over study for the determination of concentrations optimal for the clinical use. Acta Society Ophthalmologica Japonica 85: 798–804, 1981

    CAS  Google Scholar 

  • Koch H. Carteolol: β-blocker with intrinsic sympathomimetic activity. Pharmacy International 4: 226–227, 1983

    CAS  Google Scholar 

  • Kochar MS, Barboriak JJ, Kalbfleisch JH. Effects of a beta blocker with intrinsic sympathomimetic activity on serum lipids. Abstract. Clinical Research 31: 196A, 1983

    Google Scholar 

  • Kupfer C. Ophthalmic disorders. In Abrams WB & Berkow R (Eds) The Merck Manual of Geriatrics, pp. 1055–1081, Merck & Co., Inc., Rahway, 1990

    Google Scholar 

  • Lang W. Tier experimentelle Untersuchungen zur Pharmakokinetik von Carteolol. Arzneimittel Forschung 33: 286–289, 1983

    PubMed  CAS  Google Scholar 

  • Le Jeunne Cl, Bringer L, Mondjee-Tahura Z, Munera Y, Hugues FC. Effets cardio-vasculaires des collyres au timolol, au cartéolol, au métipranolol, au bétaxolol chez le sujet agé. Thérapie 43: 89–92, 1988

    PubMed  Google Scholar 

  • Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L. Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. Journal of Clinical Pharmacology 29: 97–101, 1989

    PubMed  Google Scholar 

  • Le Jeunne C, Munera Y, Hugues F-C. Systemic effects of three β-blocker eyedrops: comparison in healthy volunteers of β1- and β2-adrenoreceptor inhibition. Clinical Pharmacology and Therapeutics 47: 578–583, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lesar TS. Comparison of ophthalmic β-blocking agents. Clinical Pharmacy 6: 451–463, 1987

    PubMed  CAS  Google Scholar 

  • Lorenz von D. Zur Humanpharmakologie von Carteolol. Arzneimittel Forschung 33: 296–304, 1983

    PubMed  CAS  Google Scholar 

  • Maclure GM, Gregory JE, Munro AJ. Comparison of carteolol and timolol — a double blind study. Poster. 3rd Congress of the European Glaucoma Society, 1988

    Google Scholar 

  • Matsuda M, Ishii Y, Awata T, Fukuda M. The effect of long-term topical administration of commercial beta-blockers on the rat corneal endothelium. International Ophthalmology 13: 67–73, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mihara M, Matsuo N, Koyama T, Tsuji T. Studies on the retinal mean circulation time in eyes treated with carteolol (Mike-Ian®) by means of fluorescein video-angiography and image analysis. Therapeutic Research 10: 161–167, 1989

    Google Scholar 

  • Mills KB, Raines M, Joyce P. A single-blind, stratified, randomised non-crossover trial comparing carteolol 1% with timolol 0.25% in the long term management of glaucoma. British Journal of Clinical Practice 41 (Suppl. 51): 10–12, 1987

    Google Scholar 

  • Morita S, Iinuma M, Kido M, Sakuragi S, Kohri H, et al. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new β-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man, Arzneimittel-Forschung 12: 2380–2383, 1977

    Google Scholar 

  • Nakajima K, Abe M. Effects of carteolol on lipid metabolism. Yakuri to Chiryo 11: 1–11, 1983

    Google Scholar 

  • Negishi C, Kanai A, Nakajima A, Funahashi M, Kitazawa Y. Ocular effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients. Japanese Journal of Ophthalmology 25: 464–476, 1981

    Google Scholar 

  • Odomi M, Yamashita M, Nishina Y, Akashi S, Morita S, et al. Metabolic fate of carteolol hydrochloride (OPC-1085), a new β-adrenergic blocking agent: bioequivalence of various preparations in man. Pharmacometrics 15: 105–109, 1978

    CAS  Google Scholar 

  • Odomi M, Matsuura K, Shimizu T. Pharmacokinetics and pharmacodynamics of long-acting capsule of carteolol hydrochloride. Rinsho Yakuri 20: 427–434, 1989a

    Article  CAS  Google Scholar 

  • Odomi M, Matsuura K, Shimizu T. Pharmacokinetics of long-acting capsule of carteolol hydrochloride in a repeated study. Rinsho Yakuri 20: 435–440, 1989b

    Article  CAS  Google Scholar 

  • Ohno S, Ichiishi A, Matsuda H. Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis. Ophthalmologica 199: 41–45, 1989

    Article  PubMed  CAS  Google Scholar 

  • Pillunat L, Stodtmeister R. Effect of different antiglaucomatous drugs on ocular perfusion pressures. Journal of Ocular Pharmacology 4: 231–242, 1988

    Article  PubMed  CAS  Google Scholar 

  • Pillunat LE, Stodtmeister R. Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs (summary). Survey of Ophthalmology 33 (Suppl.): 465–466, 1989

    Article  PubMed  Google Scholar 

  • Pillunat LE, Stodtmeister R, Wilmanns I, Metzner D. Einfluß von Betarezeptorenblockern auf die Drucktoleranz des Sehnervenkopfes. Fortschritte der Ophthalmologie 85: 231–234, 1988

    PubMed  CAS  Google Scholar 

  • Rich LF. Ophthalmology. In Cassel et al. (Eds) Geriatric medicine, 2nd ed., pp. 394–404, Springer-Verlag, New York, 1990

    Google Scholar 

  • Rigeade MC. Carteolol hydrochloride: new perspective and for prevention and treatment of glaucoma. In Carteolol eye drops: its mechanism of action and efficacy, pp. 1–6, Otsuka Pharmaceutical Co. Ltd., 1990

    Google Scholar 

  • Ringham GL, Luther RR, Sennello LT, Schambelan M, Humphreys MH. A pharmacokinetic evaluation of carteolol in patients with impaired renal function. Abstract. Journal of Clinical Pharmacology 25: 468, 1985

    Google Scholar 

  • Ringham GL, Sennello LT, Jordan DC, Luther RR, Klepper MJ, et al. Pharmacokinetics of carteolol in subjects of different ages. Abstract. Journal of Clinical Pharmacology 27: 715, 1987

    Google Scholar 

  • Ritschel WA. Gerontokinetics: the pharmacokinetics of drugs in the elderly, Telford Press, Caldwell, 1988

    Google Scholar 

  • Schnarr K-D. Vergleichende multizentrische Untersuchung von Carteolol-Augentropfen mit anderen Betabiockern bei 768 Patienten unter Altagsbedingungen. Klinische Monatsblätter für Augenheilkunde 192: 167–172, 1988

    Article  PubMed  CAS  Google Scholar 

  • Schnaudigel O-E, Becker H, Fuchs H-B. Carteolol: Praxisgerechte Prüfung von Wirksamkeit und Verträglichketi eines neuen Betabiockers in der Behandlung des Glaukoms. Klinische Monatsblätter für Augenheilkunde 192: 248–251, 1988

    Article  PubMed  CAS  Google Scholar 

  • Scoville B, Krieglstein GK, Then E, Yokoyama S, Yokoyama T. Measuring drug-induced eye irritation: a simple new clinical assay. Journal of Clinical Pharmacology 25: 210–218, 1985

    PubMed  CAS  Google Scholar 

  • Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. American Journal of Ophthalmology 105: 150–154, 1988

    PubMed  CAS  Google Scholar 

  • Segawa K, Nagai T, Tanaka N, Nishiyama K. Effects of three beta-blocker eyedrops on the rabbit cornea: an electron microscope study. Clinical Therapeutics 8: 263–268, 1986

    PubMed  CAS  Google Scholar 

  • Stefánsson E. The eye. In Hazzard et al. (Eds) Principles of geriatric medicine and gerontology, 2nd ed., pp. 422–431, McGraw-Hill, New York, 1990

    Google Scholar 

  • Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, et al. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Ophthalmology 229: 258–261, 1991

    CAS  Google Scholar 

  • Stodtmeister R, Pullunat L, Wilmanns I, Neubrand M, Finger B, et al. Wirkung von Carteolol- und Timolol-Augentropfen auf die Drucktoleranz des Sehnervenkopfes. Ophthalmologica 198: 64–77, 1989

    Article  PubMed  CAS  Google Scholar 

  • Sugiyama K, Enya T, Kitazawa Y. Ocular hypotensive effect of 8-hydroxycarteolol, a metabolite of carteolol. International Ophthalmology 13: 85–89, 1989

    Article  PubMed  CAS  Google Scholar 

  • Tamagawa M, Oi A, Nishioeda R, Hatori M, Nakatsu I, et al. Acute eye irritation study of carteolol hydrochloride eye drop in rabbits. Pharmacometrics 26: 627–636, 1983

    CAS  Google Scholar 

  • Tanaka N, Ohikawa T, Hiyama T, Nakajima A. Evaluation of ocular toxicity of two beta blocking drugs, carteolol and practolol, in beagle dogs. Journal of Pharmacology and Experimental Therapeutics 224: 424–430, 1983

    PubMed  CAS  Google Scholar 

  • Tsuchisaka H, Kin K. Comparison between timolol and carteolol in patients with poorly controlled glaucoma. In Carteolol eye drops: its mechanism of action and efficacy, pp. 61–63, Otsuka Pharmaceutical Co. Ltd., 1990

    Google Scholar 

  • Tsuchisaka H, Kin K, Matsumoto S, Ishiwata T, Maeda T, et al. Multi-institutional evaluation of timolol and carteolol for glaucomas. Ganka Rinsho Iho 85: 1136–1140, 1991

    Google Scholar 

  • Ueda M, Masui M, Haruna M, Kimoto S. A pharmacological study on the acute hypotensive mechanism of pindolol. Yakuri to Chiryo 19: 499–511, 1991

    CAS  Google Scholar 

  • van Brummelen P. The relevance of intrinsic sympathomimetic activity for β-blocker-induced changes in plasma lipids. Journal of Cardiovascular Pharmacology 5: S51–S55, 1983

    Article  PubMed  Google Scholar 

  • Vanhoutte PM. Endothelium-dependent effects of carteolol. 3rd Cardiovascular Pharmacotherapy International Symposium — Carteolol Satellite Symposium, October 15, 1989. pp. 8–33, New aspects of carteolol, 1990

    Google Scholar 

  • van Husen H. Carteololhydrochlorid 1%-Augentropfen: Langzeiterfahrungen in der Behandlung des Chronischen Weitwinkelglaukoms. Klinische Monatsblätter für Augenheilkunde 189: 491–495, 1986

    Article  PubMed  Google Scholar 

  • Vinti H, Chichmanian RM, Fournier JP, Pesce A, Taillan B, et al. Systemic complications of beta-blocking eyedrops. Apropos of 6 cases. Revue de Medecine Interne 10: 41–44, 1989

    Article  PubMed  CAS  Google Scholar 

  • Watanabe K, Higashigawa Y, Fujita S. Pharmacological studies of carteolol eyedrops, a β-adrenergic blocking drug in rabbits and beagle dogs. Pharmacometrics 26: 1–8, 1983

    CAS  Google Scholar 

  • Wellstein A, Palm D, Wiemer G, Schäfer-Korting M, Mutschier E. Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma. European Journal of Clinical Pharmacology 27: 545–553, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wright S, Edgar DF, Stewart-Jones JH, Turner P. Comparison of topical betaxolol, carteolol, metipranolol and saline on intraocular pressure in normal volunteers. British Pharmacological Society, London, Dec 19–21, 1988. British Journal of Clinical Pharmacology 27: 696P–697P, 1989

    Google Scholar 

  • Yabuuchi Y, Kinoshita D. Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085): a new potent β-adrenergic blocking agent. Japanese Journal of Pharmacology 24: 853–861, 1974

    Article  CAS  Google Scholar 

  • Yamazaki A, Baba H, Tokoro T. Effects of carteolol and timolol on changes in retinal blood flow. 95th Annual Meeting of the Japanese Society of Ophthalmology, in press, 1992

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Paul Chrisp & Eugene M. Sorkin

Authors
  1. Paul Chrisp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugene M. Sorkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: A.M.V. Brooks, Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; J. Collignon-Brach, Service d’Ophthalmologie, Centre Hospitalier Universitaire de Liège, Liège, Belgium; F.I. Fraunfelder, Casey Eye Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon, USA; D.E. Gaasterland, Glaucoma and Laser Service and Worthen Center for Eye Care Research, Georgetown University Medical Center, Washington, D.C., USA; F.-C. Hugues, Service de Médecine Interne II, Hôpital Laënnec, Paris, France; E.U. Keates, Northern Ophthalmic Associates Inc., Jenkintown, Pennsylvania, USA; Y. Kitazawa, Department of Ophthalmology, School of Medicine, Gifu University, Gifu, Japan; Cl. Le Jeunne, Service de Médecine Interne II, Hôpital Laënnec, Paris, France; I.H. Leopold, Department of Ophthalmology, University of California, Irvine, California, USA; K. Segawa, Department of Ophthalmology, Shinshu University School of Medicine, Ngano-Ken, Japan.

An erratum to this article is available at http://dx.doi.org/10.1007/BF03257456.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chrisp, P., Sorkin, E.M. Ocular Carteolol. Drugs & Aging 2, 58–77 (1992). https://doi.org/10.2165/00002512-199202010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199202010-00007

Keywords

Search

Navigation